Danelia Mendieta-Cabrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danelia Mendieta-Cabrera has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Becerril-Villanueva
Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
2 shared publications - Gilberto Pérez-Sánchez
Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico
2 shared publications - Lenin Pavón
Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
2 shared publications - Sonia Mayra Pérez-Tapia
Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México City 11340, Mexico
2 shared publications - Daniel Ortuño-Sahagún
Laboratorio de Neuroinmunobiología Molecular, Instituto de Neurociencias Traslacionales, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara
1 shared publication - Dora Luz De la Cruz-Aguilera
Laboratorio de Neuroinmunoendocrinología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
- 27 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 841
Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder
Major depressive disorder (MDD) is a mood disorder that has become a global health emergency according to the World Health Organization (WHO). It affects 280 million people worldwide and is a leading cause of disability and financial loss. Patients with MDD present immunoendocrine alterations like cortisol resistance and inflammation, which are associated with alterations in neurotransmitter metabolism. There are currently numerous therapeutic options for patients with MDD; however, some studies suggest a high rate of therapeutic failure. There are multiple hypotheses explaining the pathophysiological mechanisms of MDD, in which several systems are involved, including the neuroendocrine and immune systems. In recent years, inflammation has become an important target for the development of new therapeutic options. Extracellular monomeric ubiquitin (emUb) is a molecule that has been shown to have immunomodulatory properties through several mechanisms including cholinergic modulation and the generation of regulatory T cells. In this perspective article, we highlight the influence of the inflammatory response in MDD. In addition, we review and discuss the evidence for the use of emUb contained in Transferon as a concomitant treatment with selective serotonin reuptake inhibitors (SSRIs).
- 27 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 841
Open AccessUse of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder
Major depressive disorder (MDD) is a mood disorder that has become a global health emergency according to the World Health Organization (WHO). It affects 280 million people worldwide and is a leading cause of disability and financial loss. Patients with MDD present immunoendocrine alterations like cortisol resistance and inflammation, which are associated with alterations in neurotransmitter metabolism. There are currently numerous therapeutic options for patients with MDD; however, some studies suggest a high rate of therapeutic failure. There are multiple hypotheses explaining the pathophysiological mechanisms of MDD, in which several systems are involved, including the neuroendocrine and immune systems. In recent years, inflammation has become an important target for the development of new therapeutic options. Extracellular monomeric ubiquitin (emUb) is a molecule that has been shown to have immunomodulatory properties through several mechanisms including cholinergic modulation and the generation of regulatory T cells. In this perspective article, we highlight the influence of the inflammatory response in MDD. In addition, we review and discuss the evidence for the use of emUb contained in Transferon as a concomitant treatment with selective serotonin reuptake inhibitors (SSRIs).
- 1 January 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 290, 22-25
IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients
- 1 January 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 290, 22-25
IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients